US 7507809
RNAi modulation of RSV and therapeutic uses thereof
granted A61KA61K31/713A61K9/0078
Quick answer
US patent 7507809 (RNAi modulation of RSV and therapeutic uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Mar 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/713, A61K9/0078, A61P, A61P11/00